KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition
KIBRA overexpression suppresses osteosarcoma cell proliferation and migration while impairing DNA damage repair.
Phase III
Oncology / Osteosarcoma
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The identification of KIBRA as a tumor suppressor in osteosarcoma presents a significant opportunity for drug development targeting this pathway. Its role in inhibiting cell proliferation and migration while impairing DNA damage repair could reshape treatment strategies in oncology.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor ongoing research into KIBRA-targeted therapies and their clinical implications in osteosarcoma treatment.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.